Advertisement

Studies on Steroid Receptor Coactivators in Prostate Cancer

  • Zoran CuligEmail author
  • Frédéric R. Santer
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1786)

Abstract

High expression of several androgen receptor coactivators is frequently reported in prostate cancer. Coactivators such as p300/CBP are involved in modulation of androgen receptor activity by increasing the effects of androgenic hormones and enhancing agonistic activity of antiandrogens. Studies in the field of prostate cancer frequently examined the role of p300/CBP and SRC-1 (NCOA1). In addition to their effects on steroid receptor activity, coactivators may influence other cellular functions such as migration and invasion. Steroid receptor coactivators may target various downstream genes, thus modulating proliferative and migratory responses in specific prostate cancer models. This chapter will focus on methodologies used to analyze the role of steroid receptor coactivators in prostate cancer.

Key words

Prostate cancer Coactivators Androgen receptor Proliferation Migration Invasion 

References

  1. 1.
    Visakorpi T, Hyytinen E, Koivisto P et al (1995) In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 9:401–406CrossRefPubMedGoogle Scholar
  2. 2.
    Kokontis J, Takakura K, Hay N, Liao S (1994) Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. Cancer Res 54:1566–1573PubMedPubMedCentralGoogle Scholar
  3. 3.
    Culig Z, Hobisch A, Cronauer MV, Cato AC, Hittmair A, Radmayr C, Eberle J, Bartsch G, Klocker H (1993) Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol 7:1541–1550PubMedGoogle Scholar
  4. 4.
    Hara T, Miyazaki J, Araki H, Yamaoka M, Kanzaki N, Miyamoto M (2003) Novel mutations of androgen receptor: a possible mechanisms of bicalutamide withdrawal syndrome. Cancer Res 63:149–153PubMedGoogle Scholar
  5. 5.
    Commuzzi B, Nemes C, Schmidt S et al (2004) The androgen receptor co-activator CBP is up-regulated following androgen withdrawal and is highly expressed in advanced prostate cancer. J Pathol 204:159–166CrossRefGoogle Scholar
  6. 6.
    Debes J, Commuzzi B, Schmidt LJ, Dehm SM, Culig Z, Tindall DJ (2005) p300 regulates androgen receptor-independent expression of prostate-specific antigen in prostate cancer cells treated chronically with interleukin-6. Cancer Res 65:5965–5973CrossRefPubMedGoogle Scholar
  7. 7.
    Agoulnik IU, Vald A, Bingman WE, Erdeme H, Frolov A, Smith CL, Ayala G, Ittmann MM, Weigel NL (2005) Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression. Cancer Res 65:7959–7967CrossRefPubMedGoogle Scholar
  8. 8.
    Wang S, Yuan Y, Liao L, Kuang S-Q, Tien JC-Y, O’Malley BW, Xu J (2009) Disruption of the SRC-1 gene in mice suppresses breast cancer metastasis without affecting primary tumor formation. PNAS 106:151–156CrossRefPubMedGoogle Scholar
  9. 9.
    Luef B, Handle F, Kharaishvili G et al (2016) The AR/NCOA1 axis regulates prostate cancer migration by involvement of PRKD1. Endocr Relat Cancer 23:495–508CrossRefPubMedGoogle Scholar
  10. 10.
    Santer FR, Höschele PPS, Oh SJ (2016) Inhibition of the acetyltransferase p300 and CBP reveals a targetable function for p300 in the survival and invasion pathways of prostate cancer cell lines. Mol Cancer Ther 10:1644–1655CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Experimental Urology, Department of UrologyMedical University of InnsbruckInnsbruckAustria

Personalised recommendations